Your activity: 44 p.v.
< Back
your limit has been reached. plz Donate us to allow your ip full access, Email: sshnevis@outlook.com

Selected available factor VIII products for patients with hemophilia A

Selected available factor VIII products for patients with hemophilia A
Product name Half-life (hours)* Characteristics
Standard half-life products
Advate 9 to 12 Recombinant
Hemofil M 15 Plasma-derived; mAb-purified
Kogenate FS 11 to 15 Recombinant
Koate (previously called Koate DVI) 16 Plasma-derived; chromatography purified
Kovaltry 12 to 14 Recombinant
Novoeight 8 to 12 Recombinant
Nuwiq 12 to 17 Recombinant
Recombinate 15Δ Recombinant
Xyntha 8 to 11 Recombinant
Longer-lasting products
Adynovate 13 to 16 Recombinant; PEGylated
Afstyla 10 to 14 Recombinant; single chain
Eloctate 13 to 20 Recombinant; Fc fusion
Esperoct 17 to 22 Recombinant, glycoPEGylated
Jivi 17 to 21 Recombinant; PEGylated
This table is intended as a guide for rapid identification of the product the patient is using and its characteristics and should not be used to select a product or calculate dosing. Refer to prescribing information in the product insert and to UpToDate for the use of factor replacement in patients with hemophilia. The plasma-derived products listed here are ultra-high purity (mAb purified) or high purity (chromatography purified).
FS: formulated with sucrose; mAb: monoclonal antibody.
* Half-lives are approximate. Half-lives are generally shorter for children than adults when assessed in pharmacokinetic studies. The half-life of factor VIII products without modifications to extend half-life is considered to be approximately 12 hours. The half-life should be determined for the individual patient. Refer to product information and institutional guidelines for additional dosing and monitoring information.
¶ Monoclate-P was discontinued in early 2018. Helixate FS manufacturing was discontinued in 2018, with supply available through early 2019.
Δ Adults only.
Graphic 109838 Version 9.0